News

Press Release Sep 24 2025 FORE Biotherapeutics Announces Positive Outcome From a Planned Interim Efficacy Analysis for the FORTE Basket Study Evaluating Plixorafenib as a Monotherapy for Recurrent or Progressive BRAF V600 Primary CNS Tumors Read more

Press Release Sep 12 2025 FORE Biotherapeutics Presents Phase 1/2a Plixorafenib Data Demonstrating Prolonged Duration of Effect in BRAF Altered Thyroid Cancers at American Thyroid Association® 2025 Annual Meeting Read more

Press Release Aug 27 2025 FORE Biotherapeutics to Participate in Upcoming Investor Conferences Read more

Press Release May 27 2025 FORE Biotherapeutics to Participate in the Jefferies Global Healthcare Conference Read more

Press Release May 22 2025 FORE Biotherapeutics Raises $38 Million in Series D-2 Financing for the Continued Advancement of Plixorafenib Read more

Press Release Apr 30 2025 FORE Biotherapeutics to Present Plixorafenib Abstract at the 2025 American Society of Clinical Oncology Annual Meeting Read more

Press Release Apr 25 2025 FORE Biotherapeutics Presents New Plixorafenib Results at AACR 2025 Demonstrating Pharmacodynamic Effect in Clinical Tumor Biopsies and Decreased V600E Mutant Allele Frequency in ctDNA of 85% of Patients Read more

Press Release Mar 31 2025 FORE Biotherapeutics to Present Two Plixorafenib Abstracts at the American Association for Cancer Research Annual Meeting 2025 Read more

Press Release Feb 13 2025 FORE Biotherapeutics to Participate in the Raymond James Private Biotech Symposium Read more